Imperial College London

Professor Tony Cass

Faculty of Natural SciencesDepartment of Chemistry

Professor of Chemistry



+44 (0)20 7594 5195t.cass




301KMolecular Sciences Research HubWhite City Campus






BibTex format

author = {Badve, SV and Palmer, SC and Strippoli, GFM and Roberts, MA and Teixeira-Pinto, A and Boudville, N and Cass, A and Hawley, CM and Hiremath, SS and Pascoe, EM and Perkovic, V and Whalley, GA and Craig, JC and Johnson, DW},
doi = {10.1053/j.ajkd.2016.03.418},
journal = {Am J Kidney Dis},
pages = {554--563},
title = {The Validity of Left Ventricular Mass as a Surrogate End Point for All-Cause and Cardiovascular Mortality Outcomes in People With CKD: A Systematic Review and Meta-analysis.},
url = {},
volume = {68},
year = {2016}

RIS format (EndNote, RefMan)

AB - BACKGROUND: Left ventricular mass (LVM) is a widely used surrogate end point in randomized trials involving people with chronic kidney disease (CKD) because treatment-induced LVM reductions are assumed to lower cardiovascular risk. The aim of this study was to assess the validity of LVM as a surrogate end point for all-cause and cardiovascular mortality in CKD. STUDY DESIGN: Systematic review and meta-analysis. SETTING & POPULATION: Participants with any stages of CKD. SELECTION CRITERIA FOR STUDIES: Randomized controlled trials with 3 or more months' follow-up that reported LVM data. INTERVENTION: Any pharmacologic or nonpharmacologic intervention. OUTCOMES: The surrogate outcome of interest was LVM change from baseline to last measurement, and clinical outcomes of interest were all-cause and cardiovascular mortality. Standardized mean differences (SMDs) of LVM change and relative risk for mortality were estimated using pairwise random-effects meta-analysis. Correlations between surrogate and clinical outcomes were summarized across all interventions combined using bivariate random-effects Bayesian models, and 95% credible intervals were computed. RESULTS: 73 trials (6,732 participants) covering 25 intervention classes were included in the meta-analysis. Overall, risk of bias was uncertain or high. Only 3 interventions reduced LVM: erythropoiesis-stimulating agents (9 trials; SMD, -0.13; 95% CI, -0.23 to -0.03), renin-angiotensin-aldosterone system inhibitors (13 trials; SMD, -0.28; 95% CI, -0.45 to -0.12), and isosorbide mononitrate (2 trials; SMD, -0.43; 95% CI, -0.72 to -0.14). All interventions had uncertain effects on all-cause and cardiovascular mortality. There were weak and imprecise associations between the effects of interventions on LVM change and all-cause (32 trials; 5,044 participants; correlation coefficient, 0.28; 95% credible interval, -0.13 to 0.59) and cardiovascular mortality (13 trials; 2,32
AU - Badve,SV
AU - Palmer,SC
AU - Strippoli,GFM
AU - Roberts,MA
AU - Teixeira-Pinto,A
AU - Boudville,N
AU - Cass,A
AU - Hawley,CM
AU - Hiremath,SS
AU - Pascoe,EM
AU - Perkovic,V
AU - Whalley,GA
AU - Craig,JC
AU - Johnson,DW
DO - 10.1053/j.ajkd.2016.03.418
EP - 563
PY - 2016///
SP - 554
TI - The Validity of Left Ventricular Mass as a Surrogate End Point for All-Cause and Cardiovascular Mortality Outcomes in People With CKD: A Systematic Review and Meta-analysis.
T2 - Am J Kidney Dis
UR -
UR -
VL - 68
ER -